Progen Provides Update on Cancer Candidate

Australia’s Progen Pharmaceuticals reported on enrollment in its Phase III trial with PI-88, a potential treatment of hepatocellular carcinoma.

The company said it anticipates enrolling the first patient shortly, adding there was a slight delay in starting the trial because the first testing site opened in late 2007.  

Progen does not expect the delay will have an impact on overall study timelines or registration strategy. It has received ethics approval at five trial centers, one of which is open to patient recruitment.